NFKB1 and cardiovascular disorder: Conversely, NF‐κB activation inhibits SIRT1/PGC‐1α signaling and drives aerobic glycolysis, particularly in cardiovascular diseases, where this interplay ameliorates metabolic dysfunction and oxidative stress while counteracting NF‐κB‐mediated inflammatory damage [80].